<DOC>
	<DOCNO>NCT00789802</DOCNO>
	<brief_summary>We hypothesize addition oral naproxen transdermal estradiol decrease number day unscheduled bleed experienced first-time user levonorgestrel intrauterine system ( LNG-IUC ) first 12 week use compare oral placebo . The objective study compare total number day bleed experience first time user LNG-IUC randomize oral naproxen estradiol patch compare randomize placebo first 12 week use . We enroll woman initiate LNG-IUC one 3 group , transdermal estrogen , oral naproxen oral placebo . We enroll total 114 woman , 38 group . Women keep bleed diary 16 week use calculate total number bleed spotting day . Statistical analysis perform evaluate less bleeding among treatment arm placebo arm .</brief_summary>
	<brief_title>A Randomized Controlled Trial Oral Naproxen Transdermal Estradiol Bleeding LNG-IUC</brief_title>
	<detailed_description>The levonorgestrel intrauterine system ( LNG-IUC ) one effective , reversible method contraception currently available United States . User satisfaction overall high , however often cited reason discontinuation irregular bleeding . The LNG-IUC mainly progesteronic effect uterine cavity . Morphological change endometrium observe , include stromal pseudo-decidualization glandular atrophy . These endometrial change may contribute irregular uterine bleeding experience woman use LNG-IUC . Up 14 % woman discontinue LNG-IUC within 5-year period due abnormal bleed 66 % woman request removal LNG-IUC first 6 month use . Women may less likely discontinue LNG-IUC due abnormal bleeding pattern counsel appropriately beforehand , however prospect irregular bleeding option management may dissuade woman even try LNG-IUC . A recent Cochrane review identify need investigation treatment irregular uterine bleeding cause progestin contraception . One treatment progestin-induced irregular bleed administration nonsteroidal anti-inflammatory agent ( NSAIDs ) . A 1999 study show significant decrease number bleed day woman use levonorgestrel sub-dermal implant randomize mefenamic acid 500 mg compare placebo . A 2004 study find 50 % reduction bleed depot medroxyprogesterone ( DPMA ) user randomize mefenamic acid versus placebo . There study look specifically NSAIDs prevention treatment LNG-IUC relate irregular bleeding . Naproxen antiprostaglandin commonly use gynecological practice relief dysmenorrhea use treat menorrhagia . It widely available , inexpensive , well-tolerated low incidence side effect . Previous study also show administration estrogen alone estrogen-containing oral contraceptive user subdermal levonorgestrel implant ( NorplantÂ® ) result decreased frequency irregular uterine bleeding , . A prior randomized , control trial find 0.1mg estradiol patch result clinical improvement abnormal bleeding , however find statistically significant . A randomized , controlled trial DMPA user find cyclic administration 0.1mg estradiol patch decrease irregular menstrual bleeding . In study , cyclic use estrogen may result low inconsistent serum estradiol level . Additionally , progestational mechanism action similar levonorgestrel subdermal implant LNG-IUC depot medroxyprogesterone . No study specifically address estrogen treatment irregular bleed LNG-IUC .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Must reproductive age 18 45 year Must choose LNGIUC contraception Must Englishspeaking Be willing avoid additional use exogenous hormone , oral contraceptive , duration study Be willing avoid additional use nonsteroidal antiinflammatory drug , ibuprofen aspirin duration study Be willing comply study protocol , keep bleed diary comply followup visit telephone interview schedule Be willing able provide inform consent Known suspect pregnancy Contraindication estrogen use , presence history : venous thromboembolism Arterial thrombosis Thrombophilia disorder , know family history Hypertension Migraine headaches aura focal neurologic involvement , migraine age 35 year Recent plan future major surgery result prolong immobilization study period Presence history severe hepatic disease liver tumor Known suspect estrogendependent neoplasm Vaginal bleeding unknown etiology Any cigarette smoking age 35 year Contraindications nonsteroidal antiinflammatory use , presence history : Gastrointestinal ulcer disease Renal insufficiency failure Aspirininduced asthma hypersensitivity reaction Systemic lupus erythematosus ( SLE ) mix connective tissue disorder Use anticoagulant Cardiovascular disease Use medication alter estrogen metabolism , i.e . rifampin , certain antiseizure medication Regular use NSAID Current diagnosis menorrhagia , metrorrhagia , symptomatic uterine fibroid , endometrial polyp Hypersensitivity allergy component estradiol patch Use injectable contraception within 6 month start study medication Delivery abortion previous 4 week Prior use LNGIUD Any condition , opinion investigator , would contraindicate study participation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>contraception</keyword>
	<keyword>progestin contraception</keyword>
	<keyword>intrauterine contraception</keyword>
	<keyword>unscheduled bleeding</keyword>
	<keyword>placebo</keyword>
</DOC>